Clinical trials: Nr-axSpA
Autoimmune Diseases, Ulcerative Colitis
A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
The most clinically meaningful way to discover new targets of T cells in autoimmune diseases is to study the tissues of patients with active autoimmune disease mediated organ inflammation.
- Conditions
- Autoimmune Diseases, Ulcerative Colitis, Multiple Sclerosis, Scleroderma
- Trial name
- NCT06587828
- Testing
- Companion blood samples with procedure
- Where
- 11 sites in United States
- Volunteers
- 238 people
- Sponsor
- TScan Therapeutics, Inc.
Axial Spondyloarthritis, Ankylosing Spondylitis
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
The purpose of the study is to demonstrate the long-term safety, tolerability and efficacy of bimekizumab in patients with active axial spondyloarthritis (axSpA, also known as radiographic axSpa (r-axSpA)) including ankylosing…
- Conditions
- Axial Spondyloarthritis, Ankylosing Spondylitis, r-axSpa, Nr-axSpa
- Trial name
- BE MOVING (NCT04436640)
- Testing
- Bimekizumab
- Where
- 75 sites in United States, Belgium and 12 more
- Volunteers
- 508 people
- Sponsor
- UCB Biopharma SRL
Axial Spondyloarthritis, Ankylosing Spondylitis
Vilamakitug in Spondyloarthritis Placebo-controlled Investigation for Efficacy
The goal of this clinical trial is to find out if the study drug will work as a new therapy for axSpA patients. This study is placebo-controlled, and evaluates if study drug can treat symptoms of axSpA, including global disease…
- Conditions
- Axial Spondyloarthritis, Ankylosing Spondylitis, r-axSpA, Nr-axSpA
- Trial name
- V-SPINE (NCT06526377)
- Testing
- vilamakitug
- Volunteers
- 150 people
- Sponsor
- XBiotech, Inc.
Axial Spondyloarthritis, Nonradiographic Axial Spondyloarthritis
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Patients with active Axial Spondyloarthritis without x-ray evidence of Ankylosing Spondylitis and with signs of inflammation will be randomly assigned to receive certolizumab pegol (CZP) 200 mg every two weeks or placebo.
- Conditions
- Axial Spondyloarthritis, Nonradiographic Axial Spondyloarthritis, Nr-axSpA
- Trial name
- C-AXSPAND (NCT02552212)
- Testing
- Certolizumab Pegol
- Where
- 105 sites in United States, Australia and 7 more
- Volunteers
- 317 people
- Sponsor
- UCB BIOSCIENCES GmbH